ArticleEuropean journal of nuclear medicine and molecular imaging2024
Prediction of clinically significant prostate cancer by [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07168616 (Prospective Evaluation of Istanbul PSMA PET/CT Criteria for Selecting Candidates for Active Surveillance in Low-Risk Prostate Cancer), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Evaluation of Istanbul PSMA PET/CT Criteria for Selecting Candidates for Active Surveillance in Low-Risk Prostate Cancer
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The predictive value of PSMA PET/CT in determining pathological upgrading of prostate cancer: A pooling up analysis.Frontiers in oncology · 2025Pooled it
- Predictive value of theAnnals of nuclear medicine · 2026Article
- The 68Ga-PSMA-11 PET/CT PRIMARY score for predicting pathological upgrading in ISUP grade group 1 prostate cancer: Methodological considerations and future directions.Annals of nuclear medicine · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Diagnostic value of PRIMARY score and a combined model with SUVmax in 18F-PSMA-1007 PET/CT for prostate cancer.Frontiers in medicine · 2026Article
- External Validation of Nomograms for Predicting Pelvic Lymph Node Metastases in Patients with Prostate Cancer and the Added Value of the Prostate-specific Membrane Antigen Positron Emission Tomography-based PRIMARY Score.European urology open science · 2025Article
- Risk of reclassification and novel tools in active surveillance.Asian journal of urology · 2025Review
- Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases.European journal of nuclear medicine and molecular imaging · 2025Article
- An Innovative Approach with [Diagnostics (Basel, Switzerland) · 2025Article
- Which patients with negative PSMA-PET imaging can safely avoid biopsy for prostate cancer? a novel step towards PSMA-based biopsy-free strategy.European journal of nuclear medicine and molecular imaging · 2025Article
- PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillance.Annals of nuclear medicine · 2025Article
- MRI and active surveillance: thoughts from across the pond.European radiology · 2025Review
- Improved Accuracy and Reliability of PRIMARY Scoring Using Delayed [Molecular imaging and radionuclide therapy · 2025Article
- The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Performance of PRIMARY Score based on PSMA-PET imaging in suspected prostate cancer patients with different PSA ranges: a retrospective study.American journal of nuclear medicine and molecular imaging · 2025Article
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance.European journal of nuclear medicine and molecular imaging · 2024Article
- Biomarker-driven molecular imaging probes in radiotherapy.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn our study, our aim was to investigate the role of [ MATERIALS AND
methodsWe retrospectively reviewed 147 patient records in whom [
resultsFor the 114 patients scored using PRIMARY, 19 out of 37 patients with scores of 1 and 2 (51%) were diagnosed with csPCa. Of the 77 patients with PRIMARY scores between 3 and 5, 64 (83%) had csPCa. Notably, every patient with a PRIMARY score of 5 had csPCa. PRIMARY scoring had a sensitivity of 77% and specificity of 58%, with a positive predictive value of 83%. A moderate correlation was observed between PRIMARY scores and ISUP GG (Rho = 0.54, p < 0.001). In contrast, the PIRADS score displayed a sensitivity and specificity of 86% and 25% respectively, with a positive predictive value of 68%. No substantial correlation was found between PIRADS and ISUP GG. Statistical analysis revealed a significant correlation between PRIMARY and ISUP GG (p < 0.001), but not between PIRADS and ISUP GG (p = 0.281). Comparatively, PRIMARY scoring was significantly more reliable than PIRADS scoring in identifying csPCa.
conclusion[
Indexed as
Identifiers
38112777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.